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FGFR1 amplification and the progression of
non-invasive to invasive breast cancer
Alejandro A Gru* and D Craig Allred
See related research by Jang et al., http://breast-cancer-research.com/content/14/4/R115

Abstract
The incidence of invasive breast cancer (IBC) can
be dramatically reduced by improving our abilities
to detect and treat ductal carcinoma in situ (DCIS).
Progress will be based on a detailed understanding
of molecular mechanisms responsible for tumor
progression. An interesting study by Jang and
colleagues evaluated and compared the frequency
of amplification of four oncogenes (HER2, c-MYC,
CCND1 and FGFR1) in large cohorts of pure DCIS, in
the DCIS component of IBC, and in corresponding
IBC. Of particular interest, they found a twofold
increase in FGFR1 amplification in IBC versus pure
DCIS, and significantly reduced disease-free survival
in amplified versus unamplified IBC – leading the
authors to conclude that FGFR1 plays an important
role in the development and progression of IBC.
These observations indeed provide hints that FGFR1
is important in this setting, although the issue is very
complex and far from resolved.

Invasive breast cancer (IBC) evolves through a series of
increasingly abnormal premalignant stages, over decades
in most cases [1,2]. Ductal carcinoma in situ (DCIS) is a
late stage in this evolution and the immediate precursor
for most IBC. Currently, about 60,000 new cases of DCIS
are diagnosed in the USA each year [3]. If undetected, at
least one-third of cases will progress to IBC [4]. About
200,000 cases of IBC are also diagnosed [3], and nearly all
evolve from DCIS that was not detected.
The incidence of IBC can be dramatically reduced by
improving our abilities to detect and successfully treat
DCIS, which will be based on a detailed understanding of
molecular mechanisms responsible for tumor progression.
*Correspondence: agru@path.wustl.edu
Department of Pathology & Immunology, Washington University in St. Louis
School of Medicine, St. Louis, MO 63110, USA

© 2010 BioMed Central Ltd

© 2012 BioMed Central Ltd

Although there is much to learn, recent studies have
begun to shed light on this important issue [5,6]. Among
these is an interesting study by Jang and colleagues
described in a recent issue of Breast Cancer Research,
which evaluated and compared the frequency of ampliﬁcation of four oncogenes (HER2, c-MYC, CCND1, and
FGFR1) in large cohorts of pure DCIS (n = 175), in the
DCIS component of IBC (n = 203), and in the corresponding IBC (n = 427) [1]. Ampliﬁcation was carefully
assessed by ﬂuorescence in situ hybridization on tissue
microarrays containing triplicate 2 mm cores/sample,
which is far more tissue than used in most tissue
microarray studies. Overall, they found reasonable rates
of ampliﬁcation for each oncogene in IBC consistent with
many previous studies [7]. Far fewer studies of DCIS are
available for comparison.
The main focus of the study was to compare ampliﬁcation between pure DCIS and IBC, hypothesizing that
diﬀerences may help identify genes that are important in
the transition from in situ to invasive disease. In this
regard, the most notable ﬁndings included signiﬁcantly
higher rates of HER2 ampliﬁcation in pure DCIS versus
IBC (31% vs. 20%; P = 0.004), which has been shown
before [8], and signiﬁcantly lower rates of FGFR1 in pure
DCIS versus IBC (6% vs. 13%; P = 0.02), which is novel.
These diﬀerences were more pronounced in lesions of
high histological grade (HER2 60% vs. 34%; FGFR1 7% vs.
16%). Ampliﬁcation frequencies in intrinsic molecular
subtypes of IBC were also generally consistent with
previous studies [7]. Jang and colleagues also looked at
the relationship between ampliﬁcation and clinical outcome. In these studies, ampliﬁcation of FGFR1 was associated with signiﬁcantly reduced disease-free survival in
patients with IBC (about 10% at 8 years), particularly in
hormone-receptor-positive patients, although HER2,
c-MYC, and CCND1 were not prognostic in this cohort.
The twofold elevation of FGFR1 ampliﬁcation in IBC
versus pure DCIS, and the poor prognosis in IBC, led the
authors to conclude that activation plays an important
role in the progression of breast cancer, including, in
particular, the in situ to invasive transition. This is a
reasonable conclusion in the sense that it is also

Gru and Allred Breast Cancer Research 2012, 14:116
http://breast-cancer-research.com/content/14/6/116

consistent with previous studies showing that FGFR1
activation is oncogenic for breast cancer in transgenic
mice [9], and is associated with increased invasion of
breast cancer cell lines in vitro [10] and poor prognosis in
IBC [7,11,12], especially in receptor-positive disease
[11,12].
Although our understanding of FGFR1 at the molecular
level is incomplete, important aspects are known about
its function and the consequences of gene ampliﬁcation
[13]. For example, the gene encodes a tyrosine kinase
receptor that is part of a large family of ﬁbroblast growth
factors and receptors. In a normal setting, activation of
FGFR1 can lead to transactivation of mitogen-activated
protein kinase and AKT, which collectively are essential
for breast development, including the growth and
diﬀerentiation of luminal epithelial cells. However,
increased FGFR1 activity, such as occurs through gene
ampliﬁcation, can result in increased luminal cell proliferation and, in transgenic mouse models, this hyperplasia may eventually evolve into in situ and invasive
mammary carcinomas.
In humans, the chromosomal region where FGFR1
resides, 8p11.2, is ampliﬁed in signiﬁcant proportions of
many types of cancers, including kidney cancer, lung
cancer, prostate cancer, and leukemias. The region is also
ampliﬁed in 10 to 20% of IBC [13]. However, the 8p11.2
amplicon is large and complex, and FGFR1 is only one of
several candidate oncogenes within the region [14] –
others include LSM1, PPAPDC1B, WHSC1L1, and BAG4,
which are also important in breast development and cell
cycle regulation, among other relevant functions. To
complicate matters more, only about 50% of FGFR1ampliﬁed tumors appear to overexpress the transcript
[15].
The study by Jang and colleagues provides additional
evidence of an important role for FGFR1 ampliﬁcation in
the progression of IBC [1]. The study also provides
tantalizing hints that FGFR1 may be important in the in
situ to invasive transition, which is a critical step in the
progression of a nonlethal to potentially lethal disease –
and this aspect of the study is entirely novel. Having said
this, we need to be cautious about drawing conclusions
regarding gene function and malfunction based on
correlative studies of this nature alone. For example, the
main evidence that FGFR1 is important in this study is
elevated ampliﬁcation in IBC versus DCIS. By analogous
reasoning, the elevated ampliﬁcation of HER2 observed
in DCIS versus IBC could be taken as evidence for
suppression of tumor progression, which we know is
wrong. Determining the molecular function, oncogenic
potential, and clinical signiﬁcance of FGFR1 at any stage
of breast cancer evolution will require many additional
comprehensive laboratory and clinical studies. These
studies are particularly worthwhile in the sense that we
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have eﬀective drugs to inhibit FGFR1 activity [13]. Jain
and Turner have summarized recent interesting data in
terms of the functional biology of the ﬁbroblast growth
factor receptors and development of inhibitors of these
molecules, with emphasis on challenges to successfully
target this pathway in breast cancer [16]. These could
lead to new strategies for preventing the progression of
DCIS to IBC, or restoring responsiveness of receptorpositive IBC to endocrine therapy if activation is
conﬁrmed to induce resistance [11,12] – perhaps FGFR1
will be the next HER2.
Abbreviations
DCIS, ductal carcinoma in situ; FGFR1, fibroblast growth factor receptor 1;
HER2, human epidermal growth factor receptor 2; IBC, invasive breast cancer.
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